全文获取类型
收费全文 | 48076篇 |
免费 | 3167篇 |
国内免费 | 139篇 |
专业分类
耳鼻咽喉 | 376篇 |
儿科学 | 1574篇 |
妇产科学 | 1276篇 |
基础医学 | 6713篇 |
口腔科学 | 742篇 |
临床医学 | 7533篇 |
内科学 | 8795篇 |
皮肤病学 | 1052篇 |
神经病学 | 4856篇 |
特种医学 | 848篇 |
外科学 | 4133篇 |
综合类 | 503篇 |
一般理论 | 73篇 |
预防医学 | 5912篇 |
眼科学 | 687篇 |
药学 | 2889篇 |
中国医学 | 90篇 |
肿瘤学 | 3330篇 |
出版年
2023年 | 313篇 |
2022年 | 546篇 |
2021年 | 1176篇 |
2020年 | 681篇 |
2019年 | 1145篇 |
2018年 | 1283篇 |
2017年 | 891篇 |
2016年 | 930篇 |
2015年 | 1166篇 |
2014年 | 1610篇 |
2013年 | 2452篇 |
2012年 | 3659篇 |
2011年 | 3778篇 |
2010年 | 2014篇 |
2009年 | 1748篇 |
2008年 | 3311篇 |
2007年 | 3355篇 |
2006年 | 3287篇 |
2005年 | 3077篇 |
2004年 | 2974篇 |
2003年 | 2797篇 |
2002年 | 2626篇 |
2001年 | 297篇 |
2000年 | 203篇 |
1999年 | 385篇 |
1998年 | 545篇 |
1997年 | 485篇 |
1996年 | 420篇 |
1995年 | 350篇 |
1994年 | 336篇 |
1993年 | 322篇 |
1992年 | 205篇 |
1991年 | 181篇 |
1990年 | 162篇 |
1989年 | 163篇 |
1988年 | 145篇 |
1987年 | 134篇 |
1986年 | 131篇 |
1985年 | 131篇 |
1984年 | 196篇 |
1983年 | 200篇 |
1982年 | 247篇 |
1981年 | 214篇 |
1980年 | 194篇 |
1979年 | 112篇 |
1978年 | 84篇 |
1977年 | 93篇 |
1976年 | 76篇 |
1975年 | 66篇 |
1974年 | 85篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
4.
Olga A. Klein Avril Drummond Jacqueline R. Mhizha-Murira Laura Mansford Roshan dasNair 《Neuropsychological rehabilitation》2019,29(4):491-512
While previous randomised controlled trials and meta-analyses offer only limited evidence for the effectiveness of cognitive rehabilitation, qualitative studies examining patient perspectives report more positive outcomes. This meta-synthesis of qualitative studies examined patient perspectives of cognitive rehabilitation for memory, attention, and executive function problems in people with multiple sclerosis. Using set eligibility criteria, we screened electronic databases, reference lists, and academic networks for relevant papers. Seven papers (195 participants) were selected. Two independent researchers conducted quality appraisals of papers. Data analysis, guided by the thematic synthesis approach, yielded six main themes. These suggested that patients benefitted from the group environment in rehabilitation. Cognitive rehabilitation facilitated the participants’ reflection and awareness of their cognitive deficits, and was associated with increased knowledge and understanding of their illness. Increased strategy use was reported and associated with improvements in cognitive functioning and greater confidence and perseverance. Participants reported emotional and social improvements, and felt more optimistic. Overall, these changes had a positive impact on participants’ quality of life. This synthesis of qualitative studies indicates that people with multiple sclerosis who experience cognitive deficits benefit from cognitive rehabilitation programmes. This finding must, however, be viewed in light of the limitations of this meta-synthesis. The meta-synthesis was registered in the PROSPERO database under CRD42017040148. 相似文献
5.
6.
7.
Nurse perceptions of the Nursing Delirium Screening Scale in two palliative care inpatient units: a focus group study
下载免费PDF全文
![点击此处可从《Journal of clinical nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
8.
Background
The purpose of this study was to compare the outcomes of trauma patients who were injured in a motor vehicle crash and tested positive for alcohol upon hospital arrival versus those who tested negative.Methods
Study data came from the US National Trauma Data Bank (2007–2010). Any blood alcohol concentration (BAC) found at or above the legal limit (≥0.08?g/dL) was considered “alcohol positive”, and if no alcohol was identified through testing, the patient was considered “alcohol negative”. Patients’ demographics including age >?=?14, race, gender, drug test results, systolic blood pressure, heart rate, injury severity score (ISS), and Glasgow Coma Scale (GCS) were included in the study. Propensity score and exact pair matching were performed between the groups using baseline characteristics.Results
From a total of 88,794 patients, 30.9% tested positive and 69.1% tested negative for alcohol. There were significant differences found between the groups regarding age, gender, race, and GCS (all p?<?0.001) as well as a significantly higher in-hospital mortality rate (3.5% vs. 2.7%, p?<?0.001) and median time to patient expiration (4 vs. 3 days, p?<?0.001) in the alcohol negative group. After running both matching scenarios, there was no evidence of a significant difference seen in the rates of in-hospital mortality or the median time to patient expiration between the alcohol groups in either matched comparison.Conclusion
Patients who tested positive for alcohol following a traumatic motor vehicle crash showed no significant increase in in-hospital mortality or time to expiration when compared to propensity score and exact matched patients who tested negative for alcohol. 相似文献9.
Tuberculosis (TB) remains one of a major health problem worldwide. Tuberculosis vaccine research has made an extraordinary progress over the past few years. However, there is still no replacement for the Bacillus Calmette‐Guérin vaccine, the only TB vaccine licensed for human use. Therefore, the discovery and development of new TB vaccines remains a priority. This article discusses current strategies used to diversify TB vaccines and includes discussion of the status of efforts to improve protection against Mycobacterium tuberculosis (M tb) infection or TB disease by developing new and safe TB vaccines. This article also highlights the current research efforts in immune‐enhancing approaches to improve vaccination efficacy. The development of more effective TB vaccines might have significant impact on global TB control. 相似文献
10.
van der Heijden Amber A. W. A. de Bruijne Martine C. Nijpels Giel Hugtenburg Jacqueline G. 《International journal of clinical pharmacy》2019,41(4):963-971
International Journal of Clinical Pharmacy - Background Drug-related problems (DRP) following hospital discharge may cause morbidity, mortality and hospital re-admissions. It is unclear whether a... 相似文献